Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT.

Cancer Res Treat 2009 Jun 30;41(2):100-3. Epub 2009 Jun 30.

Department of Hematooncology, Konkuk University Medical Center, Seoul, Korea.

We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2009.41.2.100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731211PMC
June 2009
8 Reads

Publication Analysis

Top Keywords

gastric adenocarcinoma
12
reported liver
8
metastases gastric
8
liver metastases
8
metabolic criteria
4
criteria metabolic
4
criteria reported
4
size criteria
4
gastrointestinal stromal
4
liver gastrointestinal
4
stromal tumors
4
fdg-pet discordance
4
activity 18f-fluorodeoxyglucose
4
metabolic activity
4
terms metabolic
4
18f-fluorodeoxyglucose positron
4
positron emission
4
tumors hepatomas
4
tomography fdg-pet
4
discordance size
4

Similar Publications